
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4926951/publications.pdf Version: 2024-02-01



VIHUA SUN

#	Article	IF	CITATIONS
1	Clinical, pathological and radiologic features of minute pulmonary meningothelial-like nodules. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1473-1479.	1.2	2
2	Prognostic implication of tumor spread through air spaces in patients with pathologic NO lung adenocarcinoma. Lung Cancer, 2022, 164, 33-38.	0.9	11
3	Evolutionary Action Score of TP53 Enhances the Prognostic Prediction for Stage I Lung Adenocarcinoma. Seminars in Thoracic and Cardiovascular Surgery, 2021, 33, 221-229.	0.4	2
4	Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nature Communications, 2021, 12, 866.	5.8	73
5	Chromobox 4 facilitates tumorigenesis of lung adenocarcinoma through the Wnt/β-catenin pathway. Neoplasia, 2021, 23, 222-233.	2.3	15
6	Is flexible bronchoscopy necessary in the preoperative workup of patients with peripheral cT1N0 subsolid lung cancer? —a prospective multi-center cohort study. Translational Lung Cancer Research, 2021, 10, 1635-1641.	1.3	2
7	Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2021, 13, 3518-3528.	0.6	49
8	Comparison of perioperative and survival outcomes between sublobar resection and lobectomy of patients who underwent a second pulmonary resection. Thoracic Cancer, 2021, 12, 2375-2381.	0.8	1
9	Clinicopathologic features and prognostic value of epidermal growth factor receptor mutation in patients with pT1a and pT1b invasive lung adenocarcinoma after surgical resection. Journal of Thoracic Disease, 2021, 13, 5496-5507.	0.6	2
10	Targeting HSPA1A in ARID2-deficient lung adenocarcinoma. National Science Review, 2021, 8, nwab014.	4.6	9
11	Does [18F] fluorodeoxyglucose–positron emission tomography/computed tomography have a role in cervical nodal staging for esophageal squamous cell carcinoma?. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 544-550.	0.4	10
12	Imaging Features Suggestive of Multiple Primary Lung Adenocarcinomas. Annals of Surgical Oncology, 2020, 27, 2061-2070.	0.7	22
13	Integrated analysis of optical mapping and whole-genome sequencing reveals intratumoral genetic heterogeneity in metastatic lung squamous cell carcinoma. Translational Lung Cancer Research, 2020, 9, 670-681.	1.3	11
14	RNA binding motif protein 10 suppresses lung cancer progression by controlling alternative splicing of eukaryotic translation initiation factor 4H. EBioMedicine, 2020, 61, 103067.	2.7	27
15	EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1781-1789.	1.2	13
16	Development and validation of nomograms for predicting overall and cancer-specific survival in young patients with non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 1404-1416.	0.6	4
17	Comparison of outcomes following segmentectomy or lobectomy for patients with clinical N0 invasive lung adenocarcinoma of 2Âcm or less in diameter. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1603-1613.	1.2	12
18	In vivo miRNA knockout screening identifies miR-190b as a novel tumor suppressor. PLoS Genetics, 2020, 16, e1009168.	1.5	14

#	Article	IF	CITATIONS
19	The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive IIIA non–small cell lung cancer. Journal of Surgical Oncology, 2019, 119, 379-387.	0.8	26
20	Distinct Prognostic Factors in Patients with Stage IÂNon–Small Cell Lung Cancer with Radiologic Part-Solid or Solid Lesions. Journal of Thoracic Oncology, 2019, 14, 2133-2142.	0.5	120
21	Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population. Journal of Thoracic Oncology, 2019, 14, 2003-2008.	0.5	52
22	Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations. Journal of Cancer Research and Clinical Oncology, 2019, 145, 747-757.	1.2	8
23	A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2115-2122.	1.2	9
24	Outcomes comparison between neoadjuvant chemotherapy and adjuvant chemotherapy in stage IIIA non-small cell lung cancer patients. Journal of Thoracic Disease, 2019, 11, 1443-1455.	0.6	9
25	tRNAâ€based prognostic score in predicting survival outcomes of lung adenocarcinomas. International Journal of Cancer, 2019, 145, 1982-1990.	2.3	18
26	Esophageal squamous cell carcinoma patients with positive lymph nodes benefit from extended radical lymphadenectomy. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 1275-1283.e1.	0.4	10
27	Lung Adenocarcinomas Manifesting as Radiological Part-Solid Nodules Define a Special Clinical Subtype. Journal of Thoracic Oncology, 2019, 14, 617-627.	0.5	151
28	Proteomic analysis of plasma exosomes to differentiate malignant from benign pulmonary nodules. Clinical Proteomics, 2019, 16, 5.	1.1	15
29	Genomic and immune profiling of pre-invasive lung adenocarcinoma. Nature Communications, 2019, 10, 5472.	5.8	127
30	Frequency and clinical significance of <i>NF1</i> mutation in lung adenocarcinomas from East Asian patients. International Journal of Cancer, 2019, 144, 290-296.	2.3	13
31	Tumor histology predicts mediastinal nodal status and may be used to guide limited lymphadenectomy in patients with clinical stage I non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2648-2656.e2.	0.4	31
32	In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3978-E3986.	3.3	78
33	A comprehensive evaluation of clinicopathologic characteristics, molecular features and prognosis in lung adenocarcinoma with solid component. Journal of Cancer Research and Clinical Oncology, 2018, 144, 725-734.	1.2	17
34	Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?. Journal of Cancer Research and Clinical Oncology, 2018, 144, 165-171.	1.2	6
35	Does delayed esophagectomy after endoscopic resection affect outcomes in patients with stage T1 esophageal cancer? A propensity score-based analysis. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 1441-1448.	1.3	14
36	Upfront surgery as first-line therapy in selected patients with stage IIIA non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1814-1822.e4.	0.4	30

#	Article	IF	CITATIONS
37	Predictors of Pathologic Tumor Invasion and Prognosis for Ground Glass Opacity Featured Lung Adenocarcinoma. Annals of Thoracic Surgery, 2018, 106, 1682-1690.	0.7	50
38	A B7 D28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma. International Journal of Cancer, 2018, 143, 2592-2601.	2.3	21
39	Development and Validation of Web-BasedÂNomograms to Precisely PredictÂConditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell Lung Cancer. Chest, 2018, 154, 501-511.	0.4	37
40	Thymoma and thymic carcinoma associated with multilocular thymic cyst: a clinicopathologic analysis of 18 cases. Diagnostic Pathology, 2018, 13, 41.	0.9	18
41	Clinical Significance of Complex Glandular Patterns in Lung Adenocarcinoma. American Journal of Clinical Pathology, 2018, 150, 65-73.	0.4	31
42	Extended Right Thoracic Approach Compared With Limited Left Thoracic Approach for Patients With Middle and Lower Esophageal Squamous Cell Carcinoma. Annals of Surgery, 2018, 267, 826-832.	2.1	49
43	Predicting prognosis of post-chemotherapy patients with resected IIIA non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 4186-4194.	0.6	5
44	Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer. Annals of Surgical Oncology, 2017, 24, 291-297.	0.7	22
45	The prognostic value of lymph node ratio and log odds of positive lymph nodes in patients with lung adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2017, 153, 702-709.e1.	0.4	33
46	Ciliated muconodular papillary tumor of the lung harboring <i>ALK</i> gene rearrangement: Case report and review of the literature. Pathology International, 2017, 67, 171-175.	0.6	50
47	Predicting the recurrence risk factors and clinical outcomes of peripheral pulmonary adenocarcinoma â‰ B Âcm with wedge resection. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1043-1051.	1.2	10
48	Development of a novel prognostic signature of long non-coding RNAs in lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1649-1657.	1.2	30
49	Should Nonsmokers Be Excluded from Early Lung Cancer Screening with Low-Dose Spiral Computed Tomography? Community-Based Practice in Shanghai. Translational Oncology, 2017, 10, 485-490.	1.7	37
50	Comparison of outcomes between muscle-sparing thoracotomy and video-assisted thoracic surgery in patients with cT1 N0 M0 lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1420-1429.e1.	0.4	13
51	The indication of completion lobectomy for lung adenocarcinoma â‰ 9 Âcm after wedge resection during surgical operation. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2095-2104.	1.2	12
52	Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations. Nature Communications, 2017, 8, 1533.	5.8	92
53	Comprehensive investigation of clinicopathologic features, oncogenic driver mutations and immunohistochemical markers in peripheral lung squamous cell carcinoma. Journal of Thoracic Disease, 2017, 9, 4434-4440.	0.6	9
54	The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive. OncoTargets and Therapy, 2017, Volume 10, 4507-4515.	1.0	13

#	Article	IF	CITATIONS
55	Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, 2579-2586.	0.6	51
56	Super enhancer associated <i>RAI14</i> is a new potential biomarker in lung adenocarcinoma. Oncotarget, 2017, 8, 105251-105261.	0.8	15
57	Effect of tumor size on prognosis of node-negative lung cancer with sufficient lymph node examination and no disease extension. OncoTargets and Therapy, 2016, 9, 649.	1.0	15
58	The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. OncoTargets and Therapy, 2016, 9, 833.	1.0	38
59	Clinical and genetic features of lung squamous cell cancer in never-smokers. Oncotarget, 2016, 7, 35979-35988.	0.8	22
60	Identification of TRA2B-DNAH5 fusion as a novel oncogenic driver in human lung squamous cell carcinoma. Cell Research, 2016, 26, 1149-1164.	5.7	26
61	Former smokers with nonâ€smallâ€cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis. Cancer Medicine, 2016, 5, 2117-2125.	1.3	8
62	The Histologic Classifications of Lung Adenocarcinomas Are Discriminable by Unique Lineage Backgrounds. Journal of Thoracic Oncology, 2016, 11, 2161-2172.	0.5	7
63	Factors Affecting Hospital Mortality in Patients with Esophagogastric Anastomotic Leak: A Retrospective Study. World Journal of Surgery, 2016, 40, 1152-1157.	0.8	13
64	Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis. Annals of Surgical Oncology, 2016, 23, 2099-2105.	0.7	108
65	Efficacy of EGFR Tyrosine Kinase InhibitorsÂin the Adjuvant Treatment forÂOperable Non-small Cell Lung Cancer by a Meta-Analysis. Chest, 2016, 149, 1384-1392.	0.4	48
66	Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations. Journal of Cancer Research and Clinical Oncology, 2016, 142, 833-843.	1.2	15
67	A propensity score matching analysis of survival following segmentectomy or wedge resection in early-stage lung invasive adenocarcinoma or squamous cell carcinoma. Oncotarget, 2016, 7, 13880-13885.	0.8	9
68	Survival following segmentectomy or lobectomy in elderly patients with early-stage lung cancer. Oncotarget, 2016, 7, 19081-19086.	0.8	24
69	Whole Exome Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma. Scientific Reports, 2015, 5, 14237.	1.6	51
70	EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis. Scientific Reports, 2015, 5, 13959.	1.6	34
71	SOX2 expression is associated with FGFR fusion genes and predicts favorable outcome in lung squamous cell carcinomas. OncoTargets and Therapy, 2015, 8, 3009.	1.0	9
72	Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review. OncoTargets and Therapy, 2015, 8, 3361.	1.0	22

#	Article	IF	CITATIONS
73	Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. Oncotarget, 2015, 6, 34300-34308.	0.8	70
74	Lung adenocarcinoma: Are skip N2 metastases different from non-skip?. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 790-795.	0.4	38
75	Is bronchoscopy necessary in the preoperative workup of a solitary pulmonary nodule?. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 36-40.	0.4	17
76	Comparison of Ivor-Lewis vs Sweet Esophagectomy for Esophageal Squamous Cell Carcinoma. JAMA Surgery, 2015, 150, 292.	2.2	73
77	LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response. Cancer Cell, 2015, 27, 698-711.	7.7	118
78	Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 1284-1291.	0.7	7
79	Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. OncoTargets and Therapy, 2014, 7, 567.	1.0	206
80	PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup. PLoS ONE, 2014, 9, e88291.	1.1	126
81	Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. OncoTargets and Therapy, 2014, 7, 513.	1.0	32
82	Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinoma. OncoTargets and Therapy, 2014, 7, 2127.	1.0	18
83	Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nature Communications, 2014, 5, 3261.	5.8	137
84	Recurrent TERT promoter mutations in non-small cell lung cancers. Lung Cancer, 2014, 86, 369-373.	0.9	27
85	YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. Nature Communications, 2014, 5, 4629.	5.8	95
86	A clinicopathologic prediction model for postoperative recurrence in stage Ia non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 1193-1199.	0.4	64
87	ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer, 2014, 84, 121-126.	0.9	194
88	Comprehensive Analysis of Oncogenic Mutations in Lung Squamous Cell Carcinoma With Minor Glandular Component. Chest, 2014, 145, 473-479.	0.4	36
89	The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma. Scientific Reports, 2014, 4, 7163.	1.6	42
90	Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old. Journal of Thoracic Disease, 2014, 6, 1396-402.	0.6	27

#	Article	IF	CITATIONS
91	Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials. OncoTargets and Therapy, 2013, 6, 1771.	1.0	7
92	Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RCS17 expression in vitro. Biochemical and Biophysical Research Communications, 2010, 396, 501-507.	1.0	101
93	MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer. Oncotarget, 0, 7, 41691-41702.	0.8	68